We determined the effect produced by microinjection of Ang-(1-7) and Ang II into two key regions of the medulla for the control of the circulation, the rostral and caudal ventrolateral medulla (RVLM and CVLM, respectively), on the baroreflex control of heart rate in anesthetized rats. Reflex bradycardia and tachycardia were induced by increases and decreases in mean arterial pressure (MAP) produced by intravenous phenylephrine and sodium nitroprusside, respectively. The pressor effects of Ang-(1-7) or Ang II (25 pmol) after RVLM microinjection (11 ± 0.8 and 10 ± 2 mmHg, respectively) were not accompanied by consistent changes in HR. In addition, RVLM microinjection of these angiotensin peptides did not alter the bradycardic or the tachycardic component of the baroreflex. CVLM microinjections of Ang-(1-7) or Ang II produced hypotension (-11 ± 1.5 and -11 ± 1.9 mmHg, respectively) that was also not accompanied by significant changes in HR. However, CVLM microinjections of angiotensins induced differential changes in the baroreflex control of HR. Ang-(1-7) attenuated the baroreflex bradycardia (0.26 ± 0.06 vs 0.42 ± 0.08 ms/ mmHg, before) and facilitated the baroreflex tachycardia (-0.86 ± 0.19 vs -0.42 ± 0.10 ms/ mmHg, before), Ang II produced the opposite effect, attenuating the tachycardia (-0.09 ± 0.06 vs -0.31 ± 0.07 ms/ mmHg, before) and facilitating the baroreflex bradycardia (0.67 ± 0.16 vs 0.41 ± 0.05 ms/ mmHg, before). The modulatory effect of Ang II and Ang-(1-7) on baroreflex sensitivity was completely abolished by peripheral administration of methyl-atropine. These results suggest that Ang II and Ang-(1-7) at the CVLM produce a differential modulation of the baroreflex control of heart rate, probably through distinct effects on the parasympathetic drive to the heart.
INTRODUCTION
The baroreceptor afferents terminate primarily in the intermediate portion of the nucleus of the solitary tract (NTS) subjacent to the area postrema in the dorsal medulla (15, 32) .
Although many brainstem and forebrain regions participate in the modulation of the sympathetic and parassympathetic outflows, regions inside ventrolateral medulla are essential for the effectiveness of the baroreceptor reflex (32) . The caudal ventrolateral medulla (CVLM) has been functionally defined as a tonicaly active sympathoinhibitory vasodepressor region (15, 32, 44) that contains a synaptic relay within the baroreflex circuit, connecting the NTS to a site of the sympathoexcitatory reticulospinal neurons, the rostral ventrolateral medulla (RVLM).
The RVLM is known to play an essential role in the tonic and reflex control of the sympathetic vasomotor tone (15, 32) . It has been functionally defined two groups of cardiovascular neurons in the CVLM: neurons that relay baroreflex inputs from the NTS to the RVLM and neurons that are insensitive to the baroreflex input (14, 44) . In addition, the CVLM depressor response, in part, is associated with vagally mediated decrease in heart rate suggesting a reciprocal connection between the main area containing parasympathetic pre-ganglionic neurons, the nucleus ambiguus, and the CVLM (47).
Among the neurotransmitters and neuromodulators that participate in the control of blood pressure at brainstem areas, growing attention has been given to the peptides of the renin-angiotensin system (RAS) (4, 21, 31, 45) . High concentrations of angiotensin AT 1 receptor and fibers containing Ang II-immunoreactivity have been described in the dorsomedial and ventrolateral areas of the medulla (2, 4, 21, 22 ). In addition, important interactions between angiotensinergic peptides and the neuronal elements of the ventrolateral medulla have been shown (47). Although the actions of Ang II are the best characterized, a role for smaller Ang peptides, such as Ang-(1-7), is emerging (4, 36, 45) . We and others have shown that both Ang II and Ang-(1-7) play mainly an excitatory action at RVLM and CVLM, acting through distinct receptors subtypes (3, 4, 18, 19, 27, 33, 38, 41) . Indeed, we have recently characterized the G protein-coupled receptor MAS as an Ang-(1-7) receptor involved in the biologic actions of this heptapeptide (37) . Regarding the baroreflex control, the only data available in the literature refer to the effect of Ang II/ or its antagonists on renal sympathetic nerve activity: it has been shown that Ang II induces facilitation of the baroreflex at the RVLM (33) (34) (35) and inhibition of the baroreflex at the CVLM (35, 40) .
It is now becoming clear that Ang-(1-7) can act as a contraregulatory peptide of the RAS since Ang-(1-7) presents several effects that are opposite to those of Ang II (16, 36) . Centrally, lateral ventricle infusion (8, 10, 29) or microinjection into the NTS (12) of Ang-(1-7) produces facilitation of the baroreflex control of heart rate, in contrast to the well known inhibitory effect induced by Ang II (4, 32) . In addition, while these peptides may induce similar pressor/ depressor effects at the RVLM/ CVLM, Ang-(1-7), acting probably through its distinct receptor (19, 36, 37) , triggers differential peripheral mechanisms (3, 28) .
In the present study, we attempted to contribute for the understanding of the role of the RAS peptides for the control of blood pressure, by evaluating the modulatory effect on the baroreflex control of heart rate produced by microinjection of Ang-(1-7) or Ang II into the two key areas for the control of the circulation at the ventrolateral medulla, the RVLM and the CVLM.
METHODS

Surgical Procedures
Experiments were performed in male Wistar rats (260-300 g) anesthetized with urethane (1.2 g/ Kg, i.p.). Rats underwent a tracheostomy and a polyethylene catheter was inserted into the abdominal aorta, through the femoral artery for arterial pressure measurement. Another catheter was inserted into the inferior cava vein, through the femoral vein for injection of drugs.
Next, the animals were placed in a stereotaxic frame (David Kopf instruments, CA) with the tooth bar 11 mm below the level of the interaural line. The dorsal surface of the brainstem was exposed by a limited occipital craniotomy and an incision of the atlanto-occipital membrane and meninges was performed, as previously described (3, 41) . The animals were kept on a heating pad and the rectal temperature was taken periodically in order to maintain a constant body temperature (aprox. 37 o C).
Arterial Pressure Measurements
Pulsatile arterial pressure was continuously monitored by a solid state strain-gauge transducer (model TP-200T, Nihon Khoden, Japan) connected to the arterial catheter. Heart rate (HR) was determined with a cardiotachometer (model AT 601G, Nihon Khoden, Japan) triggered by the arterial pressure wave. All variables, pulsatile and mean arterial pressure and HR, were recorded continuously on a direct-writing Nihon Khoden poligraph (Model CP-640G, Nihon Khoden, Japan).
Microinjections Procedures
Unilateral microinjections of Ang-(1-7), Ang II or sterile saline (vehicle -NaCl 0,9%) in a volume of 100 nL were made over a 20-30 s period into the RVLM (2.1 mm anterior, 1.8 mm lateral to the obex, and just above pia mater in the ventral surface) or into the CVLM (0.7 mm anterior, 1.8 mm lateral to the obex, and just above pia mater in the ventral surface), as previously described (3, 41) . Microinjections were made with a triple barreled glass micropipette (outside diameter= 90 -130 Mm), fixed to the stereotaxic manipulator that was inserted in the brain tissue through the dorsal surface. Experiments were made only at sites where the positioning of the micropipette produced a transitory pressor (RVLM) or depressor (CVLM) response (usually 10 -20 mmHg). For all experiments, only one site of the medulla (RVLM or CVLM) was tested per animal.
Evaluation of Baroreflex Sensitivity
Baroreflex control of HR was determined by recording reflex heart rate changes in response to transient increases or decreases in mean arterial pressure (MAP) produced by repeated bolus injections of graded doses of phenylephrine (0.25 to 5 µg, iv) (baroreflex bradycardia) or sodium nitroprusside (0.5 to 10 µg, iv) (baroreflex tachycardia) (12, 13) .
Phenylephrine or sodium nitroprusside doses were injected 1 to 2 minutes apart into a femoral vein in 0.1 mL of isotonic sodium chloride. Blood pressure and heart rate were allowed to return to basal levels before the next dose was given.
The baroreflex test was performed in different group of animals before microinjection of the peptides at the RVLM (n=5-7) or CVLM (n=5-8). The dose of phenylephrine or sodium nitroprusside that gave an intermediate MAP change (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) In these experiments, only one microinjection site of the medulla (RVLM or CVLM) was tested in each animal. Two or three microinjections (Ang II, Ang-(1-7) and/ or saline in random order) were performed in each animal with an interval of at least 30 min between each other.
To test the peripheral mechanisms involved in baroreflex changes, the muscarinic receptor antagonist, methyl-atropine (2.5 mg/ Kg), was initially injected intravenously. After a period of 15 min., the baroreflex control of HR was evaluated before and at the peak of the response induced by unilateral microinjection of Ang-(1-7) (25 pmol, n=5-6) or Ang II (25 pmol, n=6 each) into the CVLM. In these experiments, only one peptide or saline was tested in each animal.
The dose of methyl-atropine was chosen in preliminary experiments that showed that 2.5 mg/ kg, i.v., blocked the cardiovascular effects produced by acetylcholine (30 ng) for at least 60 minutes after its administration. In addition, the cardiovascular effects of acetylcholine were tested before and at the end of all experiments in order to verify the effectiveness of the muscarinic blockade.
Drugs
Ang-(1-7) and Ang II were purchased from Bachem (Torance, CA, USA) or Peninsula Laboratories (Belmont, CA, USA). Methyl-atropine nitrate, phenylephrine, sodium nitroprusside were from Sigma Chemical Company (St. Louis, MO, USA).
Ang-(1-7) and Ang II were dissolved in sterile isotonic saline (NaCl, 0.9%) at a concentration of 2 mg/ ml, and 10 Ml aliquots were stored at -20 o C. Phenylephrine and sodium nitroprusside were dissolved in sterile saline at 1 mg/ ml concentration and 100 Ml aliquots were stored at -20 o C. At the moment of the experiment, the aliquots were diluted in the desired concentrations and used only once. Methyl-atropine nitrate was dissolved in sterile saline at the moment of the experiment and used only once.
Histological Verification of Injection Sites
At the end of each experiment, 100 nL of Alcian blue dye (5%) was microinjected into the RVLM or CVLM. The animals were then killed with excess of anesthetic and the brain was carefully removed and fixed in 10% phosphate-buffered formalin. Serial coronal sections (40 - 50 µm) of the medulla oblongata were made and stained with neutral red for later histological examination. Microinjections sites were identified by the deposition of Alcian blue dye with light microscopy and referred to standard anatomical structures of the brain stem according to the atlas of Paxinos and Watson (30).
Statistical Analysis
The results are expressed as means ± SEM. Comparisons between before and after injections in the same animal were evaluated by Student's t-test for paired observations.
Comparisons among different groups were assessed by one-way ANOVA followed by the Newman-Keuls test. These analyses were performed with the software Graphpad Prism (version 4.00). The criterion for statistical significance was set at p< 0.05.
RESULTS
Effect of RVLM microinjection of Ang-(1-7) and Ang II on baroreflex sensitivity
As expected, unilateral microinjection of Ang-(1-7) and Ang II at the RVLM produced increases in blood pressure that were not accompanied by significant changes in HR (Table 1 ).
In addition, microinjection of Ang-(1-7) or Ang II into the RVLM did not alter the bradycardic or tachycardic component of the baroreflex (Table 1 ). The sensitivity of reflex bradycardia after the microinjection of Ang-(1-7) (0.57 ± 0.10 ms/ mmHg, n=6) or Ang II (0.49 ± 0.09 ms/ mmHg, n=7) was not statistically different from that observed before the microinjections (0.51 ± 0.12 ms/ mmHg, and 0.44 ± 0.11 ms/ mmHg, respectively, Table 1 ). Similarly, the sensitivity of reflex tachycardia after the microinjection of Ang-(1-7) (-0.63 ± 0.06 ms/ mmHg, n=6) or Ang II (-0.42 ± 0.13 ms/ mmHg, n=6) was similar to that produced before the microinjections (-0.59 ± 0.08 ms/ mmHg and -0.44 ± 0.05 ms/ mmHg, respectively; Table 1 ). The microinjection of saline into the RVLM did not significantly alter the bradycardic or tachycardic component of the baroreflex control (Table 1) .
The lack of a modulatory effect of angiotensins peptides on baroreflex control could be related to fact that the microinjections into the RVLM were unilateral. For these reason, in
additional group of animals we tested the effect of bilateral microinjections of Ang-(1-7) (25 pmol, n=9) into the RVLM on the baroreflex control of HR. Bilateral microinjection of Ang- (1-7) into the RVLM produced a similar pressor effect (12 ± 1.7 mmHg; baseline MAP= 86 ± 6 mmHg; n=9, data not shown) to that observed with unilateral microinjection (16 ± 1 mmHg; baseline MAP= 94 ± 5 mmHg n=6; Table 1 ). No significant effect on HR was also observed (0.3 ± 3.4 beats/ min; baseline HR= 298 ± 15 beats/ min; n=9, data not shown) and as observed with unilateral injection, bilateral microinjection of Ang-(1-7) did not significantly alter the baroreflex bradycardia (0.51 ± 0.09 ms/ mmHg vs 0.53 ± 0.09 ms/ mmHg, before microinjection, n=9, data not shown)
Effect of CVLM microinjection of Ang-(1-7) and Ang II on baroreflex sensitivity
Unilateral microinjection of Ang-(1-7) into the CVLM produced significant decrease in MAP (Baseline MAP= 110 ± 6 mmHg; RPAM= -11 ± 1.5; n=10), which was similar to that produced by Ang II (Baseline MAP= 99 ± 5 mmHg; RPAM= -11 ± 1.9; n=13). The changes in blood pressure were statistically different from that produced by saline (Baseline MAP= 97 ± 6 mmHg; -2.5 ± 0.6 mmHg, n=9). The hypotensive effect of Ang peptides was not accompanied by significant changes in HR (-5 ± 3 beats/ min and -3 ± 2 beats/ min for Ang-(1-7) and Ang II, respectively). 
Peripheral Mechanism Involved in the Baroreflex Modulatory effects Induced by CVLM
Microinjections of Ang-(1-7) or Ang II
We next evaluated the contribution of the parasympathetic tonus for the modulatory effect of the Ang peptides at CVLM on the baroreflex control of HR. Pre-treatment with the muscarinic receptor antagonist, methyl-atropine, produced the expected increase in baseline HR (Average of all animals= 378 ± 10 beats/ min vs 315 ± 11 beats/ min, before treatment; n=19) without significant change in the baseline MAP (90 ± 4 mmHg vs 95 ± 5 mmHg; n=19).
As previously described (3), the hypotensive effect of Ang-(1-7) was significantly attenuated after peripheral treatment with methyl-atropine (-3 ± 1 mmHg vs -12 ± 4 mmHg, before treatment; n=10; Table 2 ). In contrast, the hypotensive effect of Ang II at the CVLM after methyl-atropine was not statistically different from that observed before the antagonist (-9 ± 2 mmHg compared with -13 ± 3 mmHg, before treatment; n=9; Table 2 ). No significant changes in HR were induced by microinjection of angiotensins into the CVLM, before or after methylatropine treatment (Table 2 ). In addition, methyl-atropine abolished the hypotensive effect produced by intravenous injection of acetylcholine tested at the end of the experiments (-2 ± 1 mmHg compared with -22 ± 2 mmHg, before treatment; n=19; data not shown), confirming the effectiveness of the muscarinic blockade.
Methyl-atropine produced a significant attenuation of the baseline baroreflex sensitivity for both the reflex bradycardia (0.14 ± 0.02 ms/ mmHg vs 0.33 ± 0.10 ms/ mmHg, before, n=10, data not shown) and baroreflex tachycardia (-0.18 ± 0.02 ms/ mmHg vs -0.31 ± 0.04 ms/ mmHg, before, n=9, data not shown). Further, methyl-atropine prevented the modulatory effect of Ang-(1-7) and Ang II on baroreflex control of HR. Ang-(1-7) microinjection after methylatropine did not change the baroreflex bradycardia (0.12 ± 0.03 ms/ mmHg vs 0.13 ± 0.04 ms/ mmHg, before, n=4; Figure 3A) or the reflex tachycardia (-0.23 ± 0.01 ms/ mmHg vs -0.22 ± 0.02 ms/ mmHg, before, n=5; Figure 3B ). Likewise, Ang II microinjection after muscarinic blockade did not change the baroreflex bradycardia (0.09 ± 0.02 ms/ mmHg vs 0.10 ± 0.02 ms/ mmHg, before, n=5; Figure 3A) or the reflex tachycardia (-0.18 ± 0.05 ms/ mmHg vs -0.27 ± 0.06 ms/ mmHg, before, n=4; Figure 3B ). 
Histological examination
DISCUSSION
The major finding of the present study was the observation that while microinjections of Ang II and Ang-(1-7) into the RVLM did not affect the baroreflex control of heart rate, CVLM microinjections of Ang peptides induced differential changes on the bradycardic or tachycardic component of the baroreflex. While Ang-(1-7) attenuated the bradycardia and facilitaded the baroreflex tachycardia, Ang II produced opposite effects, attenuating the tachycardia and facilitating the baroreflex bradycardia. In addition, the modulatory effect of both Ang II and Ang-(1-7) on baroreflex was completely abolished by intravenous methyl-atropine. These results extended previous observations and suggest that Ang II and Ang-(1-7) produce a differential modulation on the baroreflex control of heart rate, probably through a distinct effect on the parasympathetic drive to the heart. It is well accepted that the baroreceptor reflex medullary pathway include GABAergic CVLM neurons that receive excitatory inputs from the NTS and in turn project to presympathetic neurons in the RVLM (15, 32, 44) . Most of the CVLM barosensitive neurons are GABAergic (15, 32, 44) , however some neurons are catecholaminergic or cholinergic (39, 43, 46) It is our hypothesis that angiotensin peptides modulate the activity of neurons in the CVLM that may also be involved in controlling baroreceptor modulation of the parassympathetic outflow. Figure 5 presents a simplified schematic model to illustrate our hypothesis. As the baroreflex circuit is activated by the pressor response produced by phenylephrine, an increase in the activity of the parasympathetic pre-ganglionic neurons in the NA is expected based on the well recognized NTS -NA pathway. Ang II acting on CVLM neurons would produce an increase in the activity of cardiac vagal neurons in the NA, through a direct or indirect pathway, yet to be identified. On the other hand, Ang-(1-7) would produce an opposite effect, decreasing the activity of these vagal efferents. One of the possible overall changes in the baroreflex control of HR curve induced by Ang peptides at the CVLM is also illustrated in Figure 5 .
Several studies have shown depressor responses to microinjection of excitatory amino acids or peptides in the medial and ventral portions of the lateral reticular nucleus (8, 26, 47) .
The depressor effect evoked by the microinjections of neuroactive drugs in these sites are consistent but of small magnitude in comparison to those elicited from peri-ambigual area, which are also accompanied by large alterations in HR (26,47). Future studies will be necessary to verify the existence of such pathway, connecting the ventral part of the CVLM to the parasympathetic neurons on the NA or yet other medullary sites.
The fact that Ang II and Ang-(1-7) presented distinct modulatory effects on the baroreflex is not surprising. We have shown in previous studies opposite effects for these peptides on baroreflex modulation: ICV infusion (10) or NTS microinjection (12) of Ang-(1-7) produces significant facilitation of the baroreflex bradycardia while Ang II at these same sites induces attenuation (9, 10, 11, 25) . It is also not unusual that Ang II exerts an excitatory action upon microinjection into a specific area and at the same site attenuation of the baroreflex. For example, at the NTS Ang II induces hypotensive effects, which mimics stimulation of the baroreflex, however the upon its microinjection an attenuation of the baroreflex bradycardia is observed (9, 11) . At the CVLM the hypotensive effect of Ang peptides is not accompanied by consistent changes in HR or cardiac output (3, 38) , thus suggesting that both peptides induced stimulatory effects on GABAergic CVLM neurons probably projecting to the RVLM. In fact, the hypotensive effect of Ang II at CVLM is associated with a decrease in renal sympathetic activity (48) and it is blocked by application of muscimol, a GABA agonist, into the RVLM (27). Even though the hypotensive effect of Ang-(1-7) at the CVLM is similar, previous results indicate that it involves a sympatho-nitrergic peripheral mechanism (3). Taken together, these data suggest that differential effects can result from the interaction of angiotensin peptides with barosensitive neurons, which present phasic activity, or with non-barosensitive neurons, which are tonically MAS. In these studies we can observe that the effect of Ang II was more profound than that induced by the non-selective angiotensin antagonists. Thus, considering the opposite effects evoked by these peptides, at least at the CVLM, we can conclude that the resulting effect on baroreflex induced by non-specific antagonists will be a balance between the endogenous level of Ang II and Ang-(1-7).
Other possibilities to explain our data, although more unlikely, could be related to the spread of the injectate to the NA, or yet, it could be due to the stimulation of the release of AVP, through the stimulation of CVLM neurons that project to the hypothalamus (6). In our study because the site of the microinjection is closer to the ventral surface (Figure 4 ) it is difficult to believe that the peptide could have direct assessed cholinergic vagal motor neurons in the NA.
We cannot completely ruled out the possibility that methyl-atropine have gain access to CVLM neurons upon venous injection. However, this is also a very unlike possibility considering that the quaternary structure of methyl-atropine prevents it from crossing the blood-brain barrier.
Previous studies have concluded that Ang II would not present a tonic role in the control of sympathetic tonus at the RVLM because microinjection of Losartan at this site did not induce alteration (4, 36) , or produced a significant increase in arterial pressure in normotensive rats or rabbits (18). However, subsequent studies in hypertensive animals (1) or in transgenic rats that hold changes in the RAS components (17) have shown that the role of angiotensin peptides at the RVLM may be more complex. Whereas the microinjection of losartan into the RVLM of normotensive rats produced a smaller increase in arterial pressure (18), in animals with over activity of renin-angiotensin system (such as SHR, TRG(mREN2)27, Dahl-salt) this AT 1 antagonist induced a significant reduction in arterial pressure (1, 23) .
Moreover, the microinjection of another selective AT 1 receptor antagonist, CV-11974, into the RVLM of transgenic rats with low angiotensin levels in the brain did not produce significant alteration in arterial pressure (5) . Taken together, these data suggest that besides its well-known excitatory central action, Ang II may induce an inhibitory effect depending on the endogenous level of the angiotensin peptides, at least at the RVLM.
In the present study Ang II and Ang-(1-7) microinjection into the RVLM did not alter the baroreflex control of heart rate for the bradycardic or tachycardic component. Those are not completely unexpected results since this area is primarily involved with the control of peripheral sympathetic activity and the method used in our study to evaluate the baroreflex control is more sensitive for assessing the parasympathetic component of the reflex (13) . Interestingly, after RVLM microinjection of Ang-(1-7) there was a tendency for an increase in the tachycardic component of the baroreflex, which may involve changes in the sympathetic outflow (20).
Previous studies by Head and colleagues have shown in anesthetized and conscious rabbits that RVLM microinjection of Ang II increases while microinjection of saralasin attenuates the sensitivity of the baroreflex control of renal sympathetic activity. These data suggest an endogenous role for Ang II in the modulation of the sympathetic, but not the parasympathetic, component of baroreceptor reflex at the RVLM (33-35).
In conclusion, the data presented in this study show that while microinjections of Ang peptides in the RVLM do not affect the baroreflex control of heart rate, microinjection of Ang II and Ang-(1-7) into the CVLM produce differential effects that lead to changes in the parasympathetic drive to the heart. Further, our data indicate that the non-RVLM CVLM connections, possibly with the nucleus ambiguus, may be an additional pathway for the modulatory influence of angiotensin peptides on the baroreflex control of the heart rate. Saline 5 92 ± 9 284 ± 12 3 ± 1 0.6 ± 2 0.47 ± 0.08 0.48 ± 0.06 4 98 ± 14 325 ± 18 3 ± 1.3 3 ± 1.5 -0.55 ± 0.10 -0.66 ± 0.05
Ang-(1-7) 6 94 ± 5 304 ± 11 16 ± 1* 6 ± 6 0.51 ± 0.12 0.57 ± 0.10 6 112 ± 3 321 ± 17 10 ± 1.8* 1 ± 5.0 -0.59 ± 0.08 -0.63 ± 0.06
Ang II 7 104 ± 5 300 ± 14 15 ± 3* 0.4 ± 3 0.44 ± 0.11 0.49 ± 0.09 6 104 ± 12 347 ± 13 12 ± 3.0* -4 ± 6.5 -0.44 ± 0.05 -0.42 ± 0.13
Values are mean ± SE. *p< 0.05 compared with saline group (ANOVA followed by Newman-Keuls).
R-00852-2004.R3 Table 2 . Baseline values of mean arterial pressure (MAP, mmHg) and heart rate (HR, beats/ min) and MAP and HR changes induced by microinjection of Ang-(1-7) (25 pmol), Ang II (25 pmol) or saline (100 nl) into the CVLM before and after methyl-atropine (2.5 mg/ kg, i.v.). 
Baseline Values
